Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 6, 2026Headache The Journal of Head and Face Pain

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study

View Full Paper
Ask AI
Bookmark
Share

Authors

DTDevin TeichrowUniversity of California, IrvineBKBabak KhorsandUniversity of California, IrvineKFKristina M. FanningUniversity of North Carolina Wilmington

Discussion

Loading...

Member takes

Implication

Cross-sectional data show gepants improve pain relief in chronic migraine patients, suggesting better therapy options.

Key Points

  • To compare real-world outcomes of triptans and gepants for acute migraine therapy and identify predictors of treatment response.
  • Cross-sectional analysis of migraine sufferers using the Migraine Buddy application
  • Examined 2-h pain freedom and 24-h pain relief outcomes
  • Identified demographic, clinical, and treatment-related predictors
  • Gepant users had 36% higher odds of achieving 24hPR compared to triptan users
  • No significant differences were observed in 2hPF outcomes between the two groups
  • Higher severity and frequency of migraines negatively impacted treatment effectiveness

Cite This Study

Teichrow et al. (2026) studied this question.

synapsesocial.com/papers/69faa1eb04f884e66b532b19https://doi.org/10.1111/head.70113
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex2024 · 53 citations
  2. 2Headache Assessment via Digital Platform in United States: Baseline study characteristics, diagnosis, and treatment patterns2025 · 10 citations
  3. 3Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study2022 · 362 citations
  4. 4Triptans in migraine2004 · 298 citations
  5. 5Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine2021 · 144 citations